Product Description: Asivatrep (PAC-14028) is a potent and selective transient receptor potential vanilloid type I (TRPV1) antagonist.
Applications: COVID-19-immunoregulation
Formula: C21H22F5N3O3S
References: [1]Park YH, et al. Oral and topical pharmacokinetic studies of a novel TRPV1 antagonist, PAC-14028 in rats and minipigs using liquid chromatography/tandem mass spectrometric method. J Pharm Biomed Anal. 2012 Mar 5;61:8-14./[2]Lim KM, et al. Development of PAC-14028, a novel transient receptor potential vanilloid type 1 (TRPV1) channel antagonist as a new drug for refractory skin diseases. Arch Pharm Res. 2012 Mar;35(3):393-6./[3]Yun JW, et al. TRPV1 antagonist can suppress the atopic dermatitis-like symptoms by accelerating skin barrier recovery. J Dermatol Sci. 2011 Apr;62(1):8-15.
CAS Number: 1005168-10-4
Molecular Weight: 491.47
Compound Purity: 95.16
Research Area: Inflammation/Immunology
Solubility: DMSO : 50 mg/mL (ultrasonic)
Target: TRP Channel
Deutsch
English
